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Urocortins are human homologues of urotensin I, a ﬁsh corticotropin-releasing-factor- (CRF-) like peptide secreted from the
urophysis. There are three urocortins: urocortin 1, urocortin 2, and urocortin 3 in mammals. We have shown that urocortin 1 and
urocortin 3 are endogenously synthesized in the myocardial cells of human heart and may act on CRF type 2 receptor (CRFR2)
expressed in the heart. Expression levels of urocortin 1 in the heart and plasma urocortin 1 levels are elevated in patients with heart
failure.Recentstudieshaveshownthaturocortinshavevariousbiologicalactionsinthecardiovascularsystem,suchasavasodilator
action, a positive inotropic action, a cardioprotective action against ischemia/reperfusion injury, and suppressive actions against
the renin angiotensin system and the sympathetic nervous system. Urocortins and CRFR2 may therefore be a potential therapeutic
target for cardiovascular diseases, such as congestive heart failure, hypertension, and myocardial infarction.
1.Introduction
Actionsofthecorticotropin-releasingfactor(CRF)aremedi-
ated by two types of G-protein coupled receptors: CRF type
1r e c e p t o r( C R F R 1 )[ 1] and CRF type 2 receptor (CRFR2)
[2]. CRFR1 mediates ACTH responses to stress [3, 4],
whereas CRFR2 mediates stress-coping responses including
anxiolysis, anorexia, vasodilatation, a positive inotropic
action on myocardium, and dearousal [5–7]. Mice deﬁcient
for CRFR2 show anxiety-like behavior, are hypersensitive
to stress, and have elevated blood pressure [5–7]. CRF
receptors, particularly CRFR2, are expressed in the heart and
systemic vasculature [2, 8–11]. However, CRF expression is
very low or undetectable in the heart and blood vessels,
and circulating levels of CRF in plasma are also very low.
Endogenous ligands for CRFR2 expressed in the heart and
systemicvasculaturehadbeenunknownforalongtime.This
paper is an overview of our current understanding of the
expression and function of CRF receptors and their ligands
in the cardiovascular system.
2. Discovery of Urocortins
Urotensins are peptide hormones secreted from ﬁsh uroph-
ysis, the neuroendocrine organ located in the caudal spinal
cord [12, 13]. Urotensin I was considered to be a CRF-like
ﬁshpeptide,whereasurotensinIIwasasomatostatin-likeﬁsh
peptide. Urocortin 1 (Ucn 1) was discovered from rat brain
as a mammalian homologue of ﬁsh urotensin I [14]. Ucn1
binds to both CRFR1 and CRFR2 with similar aﬃnities.
HumanUcn1has63%identitywithﬁshurotensinIand43%
identity with CRF at the amino acid level.
Furthermore, Ucn 2 (stresscopin-related peptide, SRP)
and Ucn 3 (stresscopin, SCP) were discovered by searching
the public genome databases and shown to be speciﬁc
agonists for CRFR2 [15–17]. Ucn 2/SRP [15, 17]a n dU c n
3/SCP [16, 17] were discovered by two independent research
groups, which interpreted post-translational processing sites
of the precursor proteins diﬀerently. The reported amino
acid sequences of the peptides were therefore slightly diﬀer-
ent between Ucn 2 and SRP and between Ucn 3 and SCP.2 International Journal of Endocrinology
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Figure 1: RT-PCR analysis for urocortin 1 (Ucn), CRF, CRF type1 receptor (CRF-R1), CRF type 2α receptor (CRF-R2α), and CRF type 2β
receptor (CRF-R2β) mRNAs in four human hearts (patients 1–4) in the four constituent chambers (RA, right atrium; RV, right ventricle;
LA, left atrium; LV, left ventricle). Total RNA from placenta, pituitary gland, hypothalamus, and left atrium were used as positive controls for
urocortin 1 and CRF, CRF-R1, -R2α, and -R2β, respectively. As a negative control for RT-PCR, RT was performed on total RNA samples in
the absence of reverse transcriptase enzyme (data not shown). The bottom panel shows GAPDH employed as an internal control. P: Positive
control (reproduced from [29] with kind permission from the Endocrine Society. Copyright 2002, The Endocrine Society).
HumanUcn2isa38-amino-acidpeptidethatcorrespondsto
the sequence 6–43 of human SRP, a 43-amino-acid peptide.
HumanUcn3isa38-amino-acidpeptidethatcorrespondsto
the sequence 3–40 of human SCP, a 40-amino-acid peptide.
Ucn 2 and Ucn 3 have about 20–40% homology with CRF
and Ucn 1. The homology between Ucn 2 and Ucn 3 was
about 40%.
Thus, the CRF family consists of CRF, Ucn 1, Ucn 2
(SRP), and Ucn 3 (SCP) as well as ﬁsh urotensin I and frog
sauvagine. Urocortins (Ucns) were shown to be expressed
in various tissues and cells of the human, such as brain,
pituitary, gastrointestinal tract, ovary, placenta, synovial
tissue, lymphocytes, and skin [16–28].
3. Expression of Urocortin 1 and 3 and CRF
Receptors inCardiovascularTissues
We have shown expression of Ucn 1, Ucn 3, and CRF
receptors in the human heart obtained at autopsy [29, 30].
First, reverse-transcriptase- (RT-) PCR analysis demon-
strated that Ucn 1 mRNA was expressed in the right
atrium, right ventricle, left atrium, and left ventricle in all
cases studied (Figure 1)[ 29]. However, CRF mRNA was
not detected in any of these samples. CRFR2α mRNA was
expressed in four chambers of all cases studied. A weak band
for CRFR1 mRNA was detected in the left atria of patients
2 and 3, in the left ventricles of patients 2 and 4, and in
the right ventricle of patient 4. Although CRFR1 may be
present in the heart, CRFR1 mRNA was detected in the heart
of limited cases due to the low expression levels in most
cases. CRFR2β mRNA expression was observed in the left
atrium in all cases and in the right atrium of only one out of
four cases studied (patient 2). Thus, the major CRF receptor
subtype expressed in all four chambers of the human heart
was CRFR2α. Moreover, RT-PCR analysis showed expression
of Ucn 3 mRNA in the cerebral cortex, hypothalamus,
pituitary, ventricles and atria of heart, and kidney (Figure 2)
[30]. RNA samples without reverse-transcriptase treatment
gave no band or very weak bands, indicating that eﬀects of
genomic RNA contamination into the RNA samples were
negligible.
Immunocytochemistry showed that Ucn 1 and CRF
receptor immunoreactivities were detected in the great
majorityofmyocardiaofhumanheart[29].Positiveimmun-
ostaining of Ucn 3 was also observed in the myocardium
[30] (Figures 3(a) and 3(b)). In addition to the heart, Ucn 3
was immunostained in the proximal and distal tubules of the
kidney (Figures 3(c)–3(f))[ 30]. Particularly, strong immun-
ostaining was observed in the distal tubules of the renal
cortex(Figures3(c)–3(e)).Renaltubulesintherenalmedulla
were weakly stained for Ucn 3 (Figure 3(f)). NegativeInternational Journal of Endocrinology 3
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Figure 2: RT-PCR of urocortin 3 (Ucn III) mRNA in brain, pituitary, heart, and kidneys. Cortex: cerebral cortex; Hypot: hypothalamus;
Pitui: pituitary; RA: right atrium; RV: right ventricle; LA: left atrium; LV: left ventricle; Kid 1 and Kid 2: kidneys. RT(−) indicates negative
controls (samples without reverse-transcriptase treatment). A 469 base-pair DNA fragment corresponding to 5/473 of the human urocortin
3 gene (GeneBank accession number AF361943) was ampliﬁed by RT-PCR (reproduced from [30] with kind permission from the Endocrine
Society. Copyright 2004, The Endocrine Society).
controls using normal rabbit serum instead of the Ucn 3
antiserum showed no positive immunostaining (Figures 3(g)
and 3(h)). The absorption of the antiserum with synthetic
Ucn 3 (10nmol Ucn 3/mL diluted antiserum) abolished
positive immunostaining (data not shown).
Speciﬁc radioimmunoassay for Ucn 1 and Ucn 3 could
detect respective immunoreactivity in the human heart. The
antisera against Ucn 1 and Ucn 3 were raised in rabbits
[18, 30]. The same antisera used in immunocytochemistry
were used in radioimmunoassay, respectively. The cross-
reactivity of the Ucn 1 antiserum was less than 0.001%
with CRF, Ucn 2, Ucn 3, atrial natriuretic peptide (ANP),
and other cardiovascular peptides. The radioimmunoassay
of Ucn 1 could detect changes of 10fmol/tube from zero
at 95% conﬁdence with duplicate tubes [18]. The cross
reactivity of the Ucn 3 antiserum was less than 0.001% with
CRF, Ucn 1, Ucn 2, ANP, and other cardiovascular peptides.
The radioimmunoassay of Ucn 3 could detect changes of
4.7fmol/tube from zero at 95% conﬁdence with duplicate
tubes [30].
The highest concentrations of immunoreactive- (IR-)
Ucn 1 were found in the left ventricle (1.90 ±0.5pmol/gwet
weight, mean ± SEM), followed by the right ventricle (1.26±
0.3pmol/g wet weight), the left atrium (1.21 ± 0.2pmol/g
wet weight), and the right atrium (0.92 ± 0.1pmol/g wet
weight) [29]. IR-Ucn 3 was detected in the human heart
tissues (0.74–1.15pmol/g wet weight) and kidney tissues
(1.21 ± 0.30pmol/g wet weight) [30]. IR-Ucn 3 was present
in both ventricles and atria of hearts, and no signiﬁcant
diﬀerence was noted among them. The levels of IR-Ucn
3 in the heart were comparable with the levels found in
t h eh u m a nb r a i nt i s s u e s .T h u s ,b o t hU c n1a n dU c n3a r e
diﬀusely distributed in four chambers of human hearts, and
no apparent diﬀerence was noted in the distribution between
Ucn 1 and Ucn 3 in human heart. It has not been clariﬁed
yet whether there are any diﬀerences of the physiological
signiﬁcance between Ucn 1 and Ucn 3 in the heart.
Ucn 1 mRNA expression was shown in cultured rat
cardiac myocytes and nonmyocytes [31]. IR-Ucn 1 detected
in the human heart tissues may therefore be derived from
both cardiomyocytes and other types of cells, such as
ﬁbroblasts and vascular endothelial and smooth muscle cells.
Actually, Ucn 1, Ucn 2, and Ucn 3 mRNAs were all detected
by RT-PCR in cultured human umbilical vein endothelial
cells [32]. Immunocytochemical studies showed that Ucn 1
was expressed in myometrial vascular smooth muscle cells
during pregnancy [33], and Ucn 2, but not Ucn 3 was
expressed in vascular endothelial cells of placenta [34]. Ucns
produced in the vasculature may also regulate vascular tone
in a paracrine or autocrine fashion.
IR-Ucn 1 and IR-Ucn 3 were shown to be present
in human plasma (Ucn 1, 16.6 ± 5.5pg/mL in 5 men
and 12.8 ± 1.9pg/mL in 6 nonpregnant women; Ucn 3,
51.8 ±16.0p m o l / Li n5m e n ,m e a n± SEM) [35, 36], but the
levelsweretoolowtoexertbiologicalactionsonmyocardium
or vascular tissues as circulating hormones. Ucn 1 and Ucn 3
secreted from the heart are therefore likely to act on CRFR2
expressed in the myocardium as autocrine or paracrine
factors. Wiley and Davenport showed that CRFR2 is highly
expressed in human heart using radioligand binding tech-
niques and autoradiographic studies [36]. Binding studies
using [125I] antisauvagine 30 showed the presence of high
aﬃnity of CRFR2 receptor in human left ventricle with a Kd
of 0.21 ± 0.03nM.
Bycontrast,thepredictedaminoacidsequenceofhuman
Ucn 2 (SRP) precursor lacks a consensus proteolytic cleavage
sitethatwouldallowforC-terminalprocessingofthepeptide
[15]. It has not been clariﬁed whether Ucn 2 peptide is
present in human tissues, although Ucn 2 mRNA and Ucn
2-like immunoreactivity were detected in human tissues by
RT-PCR and immunocytochemistry, respectively [34, 37].4 International Journal of Endocrinology
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Figure 3: Immunocytochemistry of urocortin 3 in human heart and kidney. (a) and (b) Myocardium (Mc) was positively stained for
uroccortin 3, whereas endocardium (Endo) and pericardial adipocytes (Adipo) were not. (c)–(e) Renal tubular cells in the renal cortex,
particularly distal tubules, were strongly stained for urocortin 3 (shown by arrows in (d)); (d) a higher magniﬁcation of (c). (f) Renal
tubular cells in the renal medulla were weakly stained for urocortin 3 (arrows). Typical urocortin 3-positive renal tubules were indicated by
arrows (d)–(f). (g) and (h) Negative controls of kidney and heart using normal rabbit serum (1:1000). (g) A serial section of kidney (c);
(h) a serial section of heart (b). Bars, 100μm (reproduced from [30] with kind permission from the Endocrine Society, Copyright 2004, The
Endocrine Society).
4. Expression of Urocortins and
CRFT ype2R ec e pt o rinth eH eartund e r
Pathological Conditions
Expression of Ucn 1 was shown to be elevated in the heart
tissues obtained from patients with heart diseases [31, 38].
Nishikimi et al. performed immunocytochemistry of Ucn
1 in heart tissues obtained at autopsy from 5 patients
without cardiovascular diseases and 5 patients with dilated
cardiomyopathy, or surgical samples of a Batista operation
in 4 patients with dilated cardiomyopathy, and showed that
Ucn 1 immunoreactivity was more intense in the myocytesInternational Journal of Endocrinology 5
of failing heart than that in myocytes of the normal heart
[31]. Ikeda et al. studied Ucn 1 expression in the diseased
heart (12 cases of hypertrophic cardiomyopathy and 42
cases of dilated cardiomyopathy) by immunocytochemistry
using endomyocardial biopsy specimens and showed that
Ucn 1 was expressed more abundantly in the diseased heart,
especiallyinhypertrophiccardiomyopathyanddilatedcardi-
omyopathy, than in the normal heart [38].
Furthermore, plasma levels of Ucn 1 are elevated in
patients with chronic heart failure [39–41]. Ng et al. studied
plasma levels of Ucn 1 in 119 patients with heart failure
and 212 age- and gender-matched controls and showed
elevated plasma Ucn 1 levels in heart failure patients (the
mean Ucn 1 levels; normal males 19.5pmol/L, heart failure
male 50.2pmol/L, normal females 14.2pmol/L, heart failure
females 21.8pmol/L) [39]. The Ucn 1 levels fell with increas-
ing age and with increasing New York Heart Association
(NYHA) functional class. Wright et al. studied plasma Ucn
1 levels in 74 patients with chronic heart failure and 225
healthy subjects and found signiﬁcant elevation of plasma
Ucn 1 levels in patients with chronic heart failure (11.1 ±
3.2pmol/L, mean ± SD), compared with healthy subjects
(7.2 ± 2.9pmol/L) [40]. In contrast to the report by Ng et
al. [39], plasma Ucn 1 levels showed stepwise increase in
proportiontoNYHAfunctionalclassesinpatientswithheart
failure. Plasma Ucn 1 levels were related to left ventricular
dimensionsandfunctionassessedbyechocardiography,such
as left ventricular end-diastolic dimension, left ventricular
end-systolic dimension, fractional shortening, and left ven-
tricularejectionfraction.Furthermore,thereweresigniﬁcant
positive relationships between plasma Ucn 1 levels and levels
of other cardiovascular hormones, including B-type natri-
uretic peptide (BNP), N-terminal proBNP, adrenomedullin,
and endothelin-1. However, the elevation of plasma Ucn
1 levels was not so marked as that of these cardiovascular
hormones in patients with heart failure. Gruson et al. also
studied plasma Ucn 1 levels in 42 fully treated heart failure
patients and 20 healthy age- and gender-matched subjects
and found elevated Ucn 1 levels in heart failure patients
(mean; 88pmol/L) compared with control (46pmol/L) [41].
Plasma Ucn 1 levels showed stepwise increase in proportion
to NYHA functional classes in patients with heart failure,
consistent with the report by Wright et al. [40], but were
not signiﬁcantly correlated with plasma levels of N-terminal
proBNP, N-terminal proatrial natriuretic peptide (proANP),
or big endothelin-1.
Elevated plasma Ucn 1 in heart failure patients may be
mainly derived from diseased heart. However, the plasma
levels may be too low to exert biological actions on
myocardiumorvasculartissuesasmentionedintheprevious
section. Ucn 1 in the diseased heart may therefore act
locally on the myocardium as an autocrine or paracrine
factor and aﬀect the myocardial function in heart failure.
CRFR2β mRNA expression was remarkably depressed in
the left ventricle of DOCA-salt spontaneously hypertensive
rats (SHRs) compared with control Wistar-Kyoto (WKY)
rats, whereas Ucn 1 mRNA expression was elevated in
DOCA-salt SHR [31]. CRFR2β mRNA expression in the
heart was decreased by lipopolysaccharide, corticosterone,
and physical restraint in rats [42]. Moreover, CRFR2β
mRNA expression in A7R5 aortic smooth muscle cells was
decreased by inﬂammatory cytokines, interleukin- (IL-) 1β,
IL-6, and tumor necrosis factor α (TNF-α)[ 42]. Coste et
al. showed that systemic administration of IL-1α and TNF-
α downregulated CRFR2 expression in the mouse heart
whereas Ucn 1 decreased CRFR2 expression in cultured
cardiomyocytes [43]. They speculated that inﬂammatory
mediators may increase expression of Ucn 1, which in turn
downregulated CRFR2 expression in the heart.
In addition to the cardiovascular and endocrine systems
and endocrine tumors [19, 44–47], Ucn 1 is expressed in
organs and cells of the immune system, such as lymphocytes
[21, 25]. There is accumulating evidence that indicates the
relation of Ucn 1 to inﬂammatory diseases. Expression
of Ucn 1 is enhanced in the tissues with inﬂammatory
diseases, such as rheumatoid arthritis and ulcerative colitis
[24, 48]. Expression of Ucn 1 was upregulated in HL-1
cardiomyocytes by lipopolysaccharide, TNF-α, and oxidative
stress [49]. Inﬂammatory mediators are important in the
pathogenesis of chronic heart failure, contributing to cardiac
remodeling and peripheral vasculardisturbances [50]. Levels
of inﬂammatory cytokines such as TNF-α,I L - 1 β,a n dI L - 6
are elevated in plasma, circulating leukocytes, and tissues of
failing myocardium in patients with chronic heart failure.
Expression of Ucn 1 mRNA was also increased after heat
shock at 42◦C in cultured rat cardiac myocytes [51]. Ucn 1
expression may therefore be induced in cardiac myocytes by
certain types of stress, such as inﬂammation and oxidative
stress.
Hypoxia induces expression of genes for various vasoac-
tive peptides such as endothelin-1 [52] and adrenomedullin
[53, 54], possibly via the transcriptional factor, hypoxia-
inducible factor 1 (HIF-1). Hypoxia did not aﬀect Ucn 1
secretion or mRNA expression in placental explants and
primary cultures of human trophoblasts [55]. Hypoxia
caused by ischemic heart disease is therefore not likely to
explain the cause for the increased expression of Ucn 1 in
diseased heart. By contrast, expression levels of Ucn 2 and
Ucn 3 mRNA were increased by hypoxic stress in cultured
rat neonatal cardiomyocytes [56]. Expression of Ucn 2 and
Ucn 3 was induced by hypoxia in primary trophoblast cell
cultures and explants via HIF-1 [57]. Moreover, B¨ uhler et al.
have shown that hypoxia induces human Ucn 2 expression
via a speciﬁc hypoxia-responsive element in the 3 -ﬂanking
region of the human Ucn 2 gene [58]. Further studies are
required to clarify whether expression of Ucn 2 or Ucn 3 is
elevated in cardiac tissues with ischemic heart disease.
There have been no reports on altered expression of Ucn
2 or Ucn 3 in diseased heart. The relation of Ucn 3 with
inﬂammation may not be so marked as that of Ucn 1. In
the colon mucosa, Ucn 3 was expressed in myenteric and
submucosal nervous plexus, blood vessels, smooth muscle
layers, and enterochromaﬃn cells but hardly detected lamina
propria inﬂammatory cells in which Ucn 1 was abundantly
expressed [59]. Moreover, no signiﬁcant elevation of Ucn 3
expression was found in the colon mucosa from ulcerative
colitis patients in contrast to Ucn 1 (Saruta and Takahashi,
unpublished observations).6 International Journal of Endocrinology
5. Potential Application of Urocortins in
theCardiovascularSystem
CRFR2 is abundantly expressed in the vasculature and all
Ucns exert potent vasodilator actions [9, 36, 60–62]. In
addition to vasodilator actions, Ucns have been shown to
exert protective actions against cell death due to various
stresses such as ischemia/reperfusion [51, 56, 63–65]. Actu-
ally, Ucn 1 was shown to enhance cardiac function during
ischemia/reperfusion [64]. These actions of Ucns may be
beneﬁcial for the treatment of cardiovascular diseases, such
as congestive heart failure, hypertension, and myocardial
infarction.
All three Ucns prevented cardiomyocytes from ischemia/
hypoxia-induced cell death and apoptosis via a MARK-
dependent pathway [56, 63] .U c n2a n dU c n3p r o -
tected cardiomyocytes from ischemia/reperfusion injury and
reduce the percentage of infarct size in the murine heart
via CRFR2 and ERK1/2-p42 and p-44 activation [64].
Cardiomyocytes isolated from CRFR2-null mice are less
resistant to ischemia/reperfusion injury, compared with
wild-type cardiomyocytes, indicating that CRFR2 is essential
for the cardioprotective actions of Ucns. Furthermore, Ucns
stimulated proliferation of cultured cardiomyocytes [66,
67]. Ucn 1 speciﬁcally induced enhanced expression of
the mitochondrial KATP channel (ATP-sensitive inwardly
rectifying potassium channel Kir 6.1) in cardiac myocytes
[68]. The mitochondrial KATP channel is believed to be
involved in the protective eﬀects. Townsend et al. showed
that Ucn 1 protected heart with reperfusion injury by
inhibiting the mitochondrial permeability transition pore
opening, possibly via a protein kinase C-mediated reduction
in oxidative stress [69].
Barry et al. have recently reported that infusion of Ucn
1 or Ucn 2 before the onset of reperfusion resulted in the
diﬀerential regulation of 66 and 141 genes, respectively,
the majority of which have not been described previously
[70]. Functional analysis demonstrated that Ucn-regulated
genes are involved in a wide range of biological responses,
including cell death, oxidative stress, and metabolism. In
addition, both Ucn 1 and Ucn 2 modulated the expression
of a host of genes involved in G-protein-coupled receptor
signaling.
Pre- and postconditioning are powerful endogenous
adaptive response of the organism whereby diﬀerent stim-
uli enhance the tolerance against various types of stress.
Cserepes et al. showed that preconditioning with Ucn 1
induced a powerful cell protective eﬀect, which was com-
parable with that of adenosine and ischemia, using isolated
neonatal rat ventricular myocytes subjected to ischemia and
reperfusion [71]. Furthermore, postconditioning with Ucn 1
was more cardioprotective than ischemic postconditioning.
The research group of Dr. Richards in New Zealand
performed a series of experiments on cardiovascular eﬀects
of Ucns in sheep as well as in human subjects [72–80].
Administration of Ucn 1, Ucn 2, or Ucn 3 induced sustained
reductions in cardiac preload and mean arterial pressure
and improvements in cardiac input and renal function
in sheep with heart failure induced by pacing [72–75].
Thus, Ucns have marked and beneﬁcial hemodynamic,
hormonal, and renal eﬀects in experimental heart failure.
These reports support the therapeutic potential of Ucns in
heart failure. Furthermore, Ucns have inhibitory eﬀects on
the sympathetic nervous system and the renin-angiotensin
system [76–79]. These inhibitory eﬀects of Ucns may also
be beneﬁcial for the treatment of heart failure. Beneﬁcial
eﬀects of Ucn 2 have been observed in human heart failure
[80]. Intravenous administration of Ucn 2 (100μgU c n2
intravenously over 1h) induced increases in cardiac output
and left ventricular ejection fraction with falls in systemic
vascular resistance and cardiac work in eight male patients
with heart failure (left ventricular ejection fraction <40%,
NYHA class II-III) [80].
Eﬀects of Ucn 2 were also shown in mice and rats with
heart failure. Bale et al. showed that Ucn 2 treatment aug-
mented heart rate, exhibited potent inotropic and lusitropic
actionsontheleftventricle, andinducedadownwardshiftof
the diastolic pressure-volume relation in mice. Ucn 2 treat-
ment also reduced systemic arterial pressure associated with
a lowering of systemic vascular resistance [81]. These eﬀects
ofUcn2werenotfoundinCRFR2-deﬁcientmice,suggesting
that these cardiovascular eﬀe c t so fU c n2w e r em e d i a t e d
by CRFR2. Ucn 2 administration to cardiomyopathic mice
(muscle-speciﬁc LIM protein-deﬁcient mice) produced sig-
niﬁcant enhancement of inotropic and lusitropic eﬀects on
left ventricular function and improved cardiac output. Yang
et al. showed that Ucn 2 had positive inotropic and lusitropic
eﬀects on mouse ventricular myocytes via activation of
CRFR2 in a cAMP/protein kinase A- and Ca2+/calmodulin-
dependent protein kinase II-dependent manner. However,
this enhancement was accompanied by Ca2+-dependent
arrhythmogenic eﬀects mediated by protein kinase A and
calmodulin-dependent protein kinase II [82]. By contrast,
Meili-Butz et al. showed that administration of Ucn 2 rapidly
improved left ventricular function and increased ventricular
ﬁbrillation threshold in failing hearts with increased propen-
sity for ventricular arrhythmias, which were isolated from
rats with hypertension-induced left ventricular hypertrophy
and heart failure [83].
In addition to heart failure, Ucn 2 has been shown
to be eﬀective for hypertension. Dieteterle et al. studied
eﬀects of acute and chronic administration of Ucn 2 in
hypertensive salt-sensitive Dahl rats and showed that Ucn 2
hadimmediateandsustainedbloodpressure-loweringeﬀects
without aﬀecting heart rate [84]. Ucn 2 administration did
not aﬀect expression of Ucn 2 and CRFR2 in left ventricle
and aorta of these rats. In addition to the direct eﬀect on
CRFR2 in the vasculature, Ucns may decrease blood pressure
through the inhibitory eﬀects on catecholamine synthesis
and secretion in adrenal medulla and the sympathetic
nervous system [37, 84]. Gu et al. showed that Ucn 2
lowered blood pressure and plasma catecholamine levels
in chromogranin A-null mice, which had hyperadrenergic
activity [84]. Dermitzaki et al. showed that CRFR1 agonists
induced catecholamine secretion whereas CRFR2 agonists
suppressed catecholamine secretion in dispersed human and
rat adrenal chromaﬃn cells [37]. Moreover, activation ofInternational Journal of Endocrinology 7
CRFR1 induced tyrosine hydroxylase, whereas activation of
CRFR2 suppressed it in human chromaﬃn cells.
6.Perspectives
Vasoconstrictor peptides, such as angiotensin II, endothelin-
1, and urotensin II, promote the progression of cardio-
vascular and renal diseases and their complications [85–
87]. Angiotensin II receptor antagonists and angiotensin-
converting enzyme inhibitors are widely used for the
treatment of cardiovascular diseases including congestive
heart failure and hypertension [86]. By contrast, vasodilator
peptides, such as ANP and adrenomedullin, have protective
actions against tissue injuries caused by various stresses and
may therefore be useful as drugs for certain cardiovascular
and renal diseases [88–91]. Actually ANP is a very eﬀective
drug for acute heart failure [89].
Ucnsarecardiovascularpeptideswhichareendogenously
synthesized in the heart and vasculature and may play
protective roles against various types of cardiovascular
stress, such as hypoxia. Ucns and Ucn-related drugs may
therefore have therapeutic potential for the treatment of
cardiovascular diseases, such as congestive heart failure,
hypertension, and myocardial infarction. Further studies are
required to clarify whether Ucns have any merits as drugs for
cardiovascular diseases over other drugs for cardiovascular
diseases, including ANP, and which Ucn is the most eﬀective
for this purpose among three Ucns.
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